Parabilis Medicines prices upsized IPO at $20 per share, raising $670 million above expected range
Parabilis' successful IPO highlights strong investor confidence in biotech innovation, potentially accelerating advancements in oncology treatments. The post Parabilis Medicines prices upsized IPO at $20 per share, raising $670 million above expected range appeared first on Crypto Briefing.